Radiopharm Theranostics (ASX:RAD) 3-Year Share Buyback Ratio : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Radiopharm Theranostics's current 3-Year Share Buyback Ratio was 0.00%.

The historical rank and industry rank for Radiopharm Theranostics's 3-Year Share Buyback Ratio or its related term are showing as below:

During the past 3 years, Radiopharm Theranostics's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was 0.00%. And the median was 0.00%.

ASX:RAD's 3-Year Share Buyback Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: -9.7
* Ranked among companies with meaningful 3-Year Share Buyback Ratio only.

Competitive Comparison of Radiopharm Theranostics's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, Radiopharm Theranostics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Radiopharm Theranostics 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Radiopharm Theranostics (ASX:RAD) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Radiopharm Theranostics 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

RADX:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Radiopharm Theranostics Headlines

No Headlines